RxDoctor Payments Data

Gary Bonacquisti, MD

Family Medicine · Rockwall, TXNPI 1881652311

Payments from drug & device makers

$2,037in general payments, 2019–2025

Across 157 payments — averaging $12.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$410
  • Novo Nordisk$276
  • GSK$256
  • Merck$181
  • AstraZeneca$161
  • Pfizer$128
  • plus $625 from 18 others

What the payments were for

  • Food & beverage$2,031100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,037 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$78,196
Medicare patients
247
Services billed
764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide185$211,410
TrulicityDulaglutide120$137,074
JardianceEmpagliflozin48$55,684
MounjaroTirzepatide44$52,176
JanuviaSitagliptin Phosphate44$37,684
FarxigaDapagliflozin Propanediol38$30,911
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$19,451
LinzessLinaclotide19$17,755
Breo ElliptaFluticasone/Vilanterol13$8,639
SymbicortBudesonide/Formoterol Fumarate14$5,143
Atorvastatin Calcium517$4,457
Levothyroxine Sodium523$4,402
Eszopiclone87$3,559
Febuxostat16$2,864
Montelukast Sodium297$2,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$276$211,410185 claims
Lilly USA, LLCTrulicity, Mounjaro$57$189,250164 claims
MerckJanuvia$181$37,68444 claims
AstraZenecaFarxiga, Symbicort$161$36,05452 claims
GSKTrelegy Ellipta, Breo Ellipta$256$28,09043 claims
AbbVieLinzess, Synthroid$410$19,86542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Rockwall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →